Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells

被引:29
|
作者
Yotnda, P
Mintz, P
Grigoriadou, K
Lemonnier, F
Vilmer, E
Langlade-Demoyen, P
机构
[1] Inst Pasteur, Unite Immun Cellulaire Antivirale, F-75724 Paris 15, France
[2] Ctr Integre Rech Bioclin SIDA, Paris, France
[3] Hop Robert Debre, Serv Hematol, F-75019 Paris, France
关键词
acute lymphoblastic leukemia; cytotoxic T lymphocyte; apoptosis; anergy; Th1/Th2;
D O I
10.1016/S0301-472X(99)00083-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We previously showed that a specific antileukemia T-cytotoxic response is spontaneously elicited in acute lymphoblastic leukemia (ALL) patients and might contribute to host antileukemia defense, even though it is insufficient for tumor growth control. In this study, we report that multifactorial factors account for some of the acquired immune defects seen in ALL patients. In bone marrow of ALL patients, T cells do not express CD40L and CD25 markers, their apoptosis rate is increased, and a predominance of a CD4 cell subset expressing a Th2 phenotype is detected. A lack of expression of B7-1 molecules and other activation molecules is observed on all ALL blasts. These different parameters combined lead to in vivo dysfunction of T-cell proliferative and cytotoxic activity. (C) 1999 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:1375 / 1383
页数:9
相关论文
共 50 条
  • [41] Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia
    Algeri, Mattia
    Del Bufalo, Francesca
    Galaverna, Federica
    Locatelli, Franco
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (12) : 945 - 956
  • [42] T-Cell Acute Lymphoblastic Leukemia-Current Concepts in Molecular Biology and Management
    Shiraz, Parveen
    Jehangir, Waqas
    Agrawal, Vaibhav
    BIOMEDICINES, 2021, 9 (11)
  • [43] Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma
    Candoni, Anna
    Lazzarotto, Davide
    Petruzzellis, Giuseppe
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) : 751 - 756
  • [44] T-cell acute lymphoblastic leukemia in a child with ataxia-telangiectasia - Case report
    Janic, Dragana
    Dokmanovic, Lidija
    Jovanovic, Nada
    Lazic, Jelena
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (10) : 713 - 715
  • [45] Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia
    Moharram, Sausan A.
    Shah, Kinjal
    Khanum, Fatima
    Marhall, Alissa
    Gazi, Mohiuddin
    Kazi, Julhash U.
    CANCER LETTERS, 2017, 405 : 73 - 78
  • [46] Apoptosis inhibition in T-cell acute lymphoblastic leukemia by UNC13B
    Wang, Xiaobo
    Yuan, Lihua
    Ye, Yongbin
    Lu, Bo
    Xu, Xiaojun
    MATERIALS EXPRESS, 2022, 12 (05) : 675 - 682
  • [47] CAR T-Cell Therapy Pediatric patients with relapsed and refractory acute lymphoblastic leukemia
    Callahan, Colleen
    Baniewicz, Diane
    Ely, Beth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (02) : 22 - 28
  • [48] Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors
    Dagklis, Antonis
    Demeyer, Sofie
    De Bie, Jolien
    Radaelli, Enrico
    Pauwels, Daphnie
    Degryse, Sandrine
    Gielen, Olga
    Vicente, Carmen
    Vandepoel, Roel
    Geerdens, Ellen
    Uyttebroeck, Anne
    Boeckx, Nancy
    de Bock, Charles E.
    Cools, Jan
    BLOOD, 2016, 128 (23) : 2642 - 2654
  • [49] Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia
    Fabrizio, Vanessa A.
    Curran, Kevin J.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (03)
  • [50] Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells
    Wang, Xiaolei
    Lou, Kaiyan
    Song, Xiaodong
    Ma, Huijuan
    Zhou, Xinyi
    Xu, Huan
    Wang, Wei
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 396